Open AccessProgrammed Death-Ligand 1 Protein and Colorectal Cancer Patient Survival Rates n Hasan Sadikin Hospital Bandung
Author(s) -
Vandra Bina Riyanda,
Reno Rudiman,
Nurhayat Usman
Publication year - 2021
Publication title -
bioscientia medicina
Language(s) - English
Resource type - Journals
ISSN - 2598-0580
DOI - 10.37275/bsm.v6i1.437
Subject(s) - colorectal cancer , medicine , malignancy , cancer , oncology , ligand (biochemistry) , cause of death , immune system , receptor , gastroenterology , immunology , disease
Background: According to the American Cancer Society, Colorectal Cancer (CRC) is the third leading cause of cancer death in men and women in the United States. In Indonesia, CRC ranks as the third most common malignancy in both men and women. Programmed death-ligand 1(PD-L1) is a trans-membrane receptor ligand and negative regulatory signal for T cells that is elevated in several tumors including CRC and binds to programmed death 1 (PD-1) on T cells, B cells, dendritic cells and natural killer T cells. PD-L1 expression was found in tumor cells and tumor cells that infiltrate immune cells in several malignancies, including CRC.
Methods: This study is a comparative analytic cross sectional study with consecutive sampling method. This study was conducted at Hasan Sadikin Hospital, Bandung from September to October 2021. Further statistical analysis was done SPSS version 25.0 for Windows (SPSS Inc., Chicago, Ill., USA).
Results: The total sample in this study was 50 subjects with colorectal cancer patients at RSHS. The number of CRC patients who expressed PD-L1 were 23 (46%) and 27 subjects (54%). The majority of cancer patient survival 2 Years was 38 subjects (76.0%) and survivors of more than 2 years was 12 subjects (24.0%).
Conclusion: There is no significant relationship between PD-L1 and survival rates in CRC patients.